Q4 Earnings Estimate for Vericel Issued By Leerink Partnrs

Vericel Co. (NASDAQ:VCEL) – Equities research analysts at Leerink Partnrs decreased their Q4 2024 earnings per share (EPS) estimates for Vericel in a research report issued to clients and investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the biotechnology company will post earnings per share of $0.32 for the quarter, down from their previous forecast of $0.33. The consensus estimate for Vericel’s current full-year earnings is $0.13 per share. Leerink Partnrs also issued estimates for Vericel’s Q4 2025 earnings at $0.36 EPS, FY2025 earnings at $0.38 EPS, FY2026 earnings at $0.80 EPS, FY2027 earnings at $1.34 EPS and FY2028 earnings at $1.79 EPS.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The firm had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million.

Several other research analysts have also weighed in on the stock. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a report on Friday, November 8th. TD Cowen lifted their price target on Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Canaccord Genuity Group reissued a “buy” rating and issued a $60.00 price objective on shares of Vericel in a report on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Vericel in a report on Friday, November 8th. Finally, Stephens boosted their price target on Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Vericel currently has a consensus rating of “Moderate Buy” and an average target price of $59.71.

Vericel Trading Down 1.7 %

VCEL stock opened at $57.76 on Tuesday. The company has a market capitalization of $2.85 billion, a P/E ratio of 962.83 and a beta of 1.66. The firm has a 50 day simple moving average of $46.92 and a 200-day simple moving average of $47.22. Vericel has a twelve month low of $32.31 and a twelve month high of $61.49.

Institutional Trading of Vericel

Several large investors have recently added to or reduced their stakes in VCEL. International Assets Investment Management LLC grew its stake in shares of Vericel by 4,126.7% in the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 619 shares in the last quarter. CWM LLC lifted its holdings in Vericel by 319.0% in the second quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 504 shares during the period. Farther Finance Advisors LLC grew its position in Vericel by 48.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 405 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 322 shares during the period. Finally, Meeder Asset Management Inc. bought a new stake in shares of Vericel during the 3rd quarter worth about $92,000.

Insider Activity

In other news, Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $60.00, for a total transaction of $150,000.00. Following the completion of the transaction, the director now owns 26,595 shares of the company’s stock, valued at approximately $1,595,700. The trade was a 8.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Steven C. Gilman sold 5,833 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total transaction of $235,361.55. Following the completion of the sale, the director now directly owns 11,000 shares in the company, valued at approximately $443,850. This trade represents a 34.65 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,666 shares of company stock valued at $1,350,764. 7.20% of the stock is currently owned by insiders.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.